Paranasal sinus pathogens in children with cystic fibrosis: do they relate to lower respiratory tract pathogens and is eradication successful?

J Cyst Fibros. 2014 Jul;13(4):449-54. doi: 10.1016/j.jcf.2014.03.003. Epub 2014 Apr 6.

Abstract

Background: The study aims were to assess the association of microflora between the paranasal sinus and the lower airways of children attending a regional paediatric cystic fibrosis centre and to determine the performance of an eradication treatment protocol for positive paranasal sinus samples.

Method: Paired nasal lavage and lower airway samples (cough swabs or sputum) were taken from 54 children with cystic fibrosis (median age 11 years). Positive paranasal sinus samples received eradication treatment, using oral and sinonasal nebulised antibiotics.

Results: A correlation between paranasal sinus and lower airways was detected in 33/54 paired timed samples (p<0.02). Of 4/54 children who reported sinus symptoms, only 2 had paranasal sinus positive samples. 28 positive nasal lavage samples cultured 8 Pseudomonas aeruginosa (PA), 8 Staphylococcus aureus (SA) and 12 other bacterial pathogens. Eradication using sinonasal nebulised antibiotics and oral antibiotics showed a success of 14/21 (67%) treated paranasal sinus positive samples at 1 month & 3 months after treatment. Success rate was 75% in the PA group and 71% in the SA group. Ongoing monitoring with nasal lavage will continue.

Conclusion: There was agreement between pathogens or lack of them found in the paranasal sinus and lower airways. Paranasal infection is often asymptomatic in children with cystic fibrosis. The eradication protocol for paranasal sinus pathogens had a good success rate.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / drug therapy
  • Cystic Fibrosis / microbiology*
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Paranasal Sinuses / microbiology*
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / mortality
  • Pseudomonas aeruginosa / isolation & purification*
  • Respiratory Tract Infections / complications
  • Respiratory Tract Infections / drug therapy
  • Respiratory Tract Infections / microbiology*
  • Retrospective Studies
  • Sputum / microbiology*
  • Staphylococcal Infections / complications
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / microbiology
  • Staphylococcus aureus / isolation & purification*

Substances

  • Anti-Bacterial Agents